Core Insights - The report highlights a significant shift in the pharmaceutical and biotechnology industry, moving from a follower to a leader in innovation, particularly in the context of international expansion and high-end product development [3][4] - The overall industry revenue and profit growth are expected to rebound after a period of decline, driven by the recovery of innovative drugs and the CXO sector [3][4] Industry Performance and Valuation Dynamics - In the first three quarters of 2025, the pharmaceutical sector experienced a notable divergence in performance across sub-sectors, with innovative drugs and CXO showing signs of recovery while others lagged [3][15] - The total revenue for 461 A-share listed companies in the pharmaceutical sector is projected to reach CNY 24,640 billion in 2024, with a slight decline of 0.7% year-on-year [15][18] - The overall valuation of the pharmaceutical sector remains low compared to historical averages, with innovative drugs benefiting from expectations of business development (BD) transactions [3][4][15] Innovative Drugs - The report emphasizes that the rapid development and lower costs of new drug development in China have positioned the country as a global leader, contributing approximately one-third of the global innovative R&D pipeline in 2025 [4][14] - The introduction of the commercial insurance innovative drug directory in 2025 is expected to stimulate payment growth for innovative drug products [3][4] CXO Sector - The CXO market is witnessing improved supply and demand dynamics, with CDMO companies entering a high-growth cycle due to strong demand for new molecular entities [4][15] - Key players in the CDMO space, such as WuXi AppTec, are highlighted for their robust project pipelines and market positioning [4][15] Life Sciences Upstream - The recovery in downstream demand is driving revenue growth in the life sciences sector, with companies actively pursuing mergers and acquisitions to expand their market presence [4][15] - Companies like Bide Pharmaceutical and Haoyuan Pharmaceutical are noted for their strong cash reserves and strategic acquisition activities [4][15] AI in Healthcare - The report discusses the impact of AI in healthcare, driven by government policies and the development of large-scale AI models, with companies like JD Health and Yimaitong being key players [4][5] High-End Medical Equipment - The high-end medical equipment sector is expected to benefit from a recovery in domestic procurement, import substitution, and accelerated international expansion [4][5] - Companies such as United Imaging and Kaili Medical are identified as potential beneficiaries of these trends [4][5] Orthopedic Consumables - The orthopedic market is expanding due to an aging population, with the negative impacts of centralized procurement clearing up, leading to a resurgence in demand for robotic-assisted surgeries [4][5] Traditional Chinese Medicine - Some traditional Chinese medicine companies are showing signs of revenue and profit improvement, driven by seasonal demand and adjustments in the essential medicine directory [4][5]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2]. Core Viewpoints - The recent performance of the pharmaceutical sector has been sluggish, with the innovative drug sector experiencing a significant rise in expectations earlier this year, now undergoing a correction. However, innovative medical devices are expected to benefit from ongoing government support for medical equipment upgrades and accelerated domestic replacement of high-end medical devices, alongside continuous expansion into overseas markets. A recovery is anticipated starting in Q3 2025, with performance gradually improving in 2026 [3][9]. - The high-end medical device sector is driven by the recovery of in-hospital procurement, suggesting a focus on companies such as United Imaging, Shandong Weigao, and Mindray Medical. The demand for consumer medical devices is gradually recovering, with a shift in market share from imported brands, indicating potential in companies like Kefu Medical and Yuyue Medical. The orthopedic consumables market has reached a price floor, with opportunities for market share growth in orthopedic robotics and overseas expansion, highlighting companies like Aikang Medical and Chuangli Medical [3][9]. - The pharmaceutical equipment sector is undergoing a cyclical recovery, with rapid overseas growth opening new avenues for growth. Domestic margins are expected to stabilize and profitability to improve, with a return to rational competition anticipated from late 2024. The recovery in innovative drug financing and frequent business development transactions are expected to drive a revival in contract manufacturing organizations (CMOs), positively impacting the pharmaceutical equipment industry. Additionally, global strategic safety backups and commitments from multinational pharmaceutical companies to invest in the U.S. market are projected to accelerate fixed asset expenditures in the pharmaceutical sector over the next three years, with a focus on companies like Senson International and Dongfulong [3][9]. - In the CXO and upstream life sciences supply chain, leading global CXO companies such as WuXi AppTec and Kanglong Huacheng are highlighted. Domestic clinical CRO leaders like Tigermed and Pruce are also recommended, along with resource-based CXOs such as Zhaoyan New Drug and Mediso. The upstream life sciences supply chain includes companies like Baipusais and Haier Biomedical [3][9]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's return was -1.04% last week, ranking 17th among 31 sub-industry indices. The medical services sub-sector had the highest weekly return at 1.67%, while the pharmaceutical commercial sub-sector had a return of -4.26% [3][9]. Industry Trends - The report emphasizes the ongoing low performance of the pharmaceutical sector, particularly in innovative drugs, while highlighting the potential recovery in innovative medical devices and the pharmaceutical equipment sector [3][9]. Recommendations - Specific companies to watch include United Imaging, Mindray Medical, Kefu Medical, and Aikang Medical in the high-end medical device sector, as well as Senson International and WuXi AppTec in the pharmaceutical equipment and CXO sectors [3][9].

Group 1 - The core viewpoint of the article emphasizes the importance of the "Action Plan for Promoting High-Quality Development of Service Outsourcing," which aims to cultivate internationally competitive leading service outsourcing companies by 2030 [1] - The plan aims to enhance the digitalization, intelligence, greening, and integration of service outsourcing, significantly increasing employment and making service outsourcing a key component of innovative service trade and digital trade development [1] - Emerging technologies such as cloud computing, big data, artificial intelligence, and the Internet of Things will deeply integrate into the service outsourcing industry, driving its transformation towards digitalization, intelligence, and high-end services [1] Group 2 - The application of generative AI technology is expected to greatly improve the efficiency and quality of service outsourcing, facilitating the industry's shift towards intelligence and platformization [1] - The traditional service model will upgrade to an "industry empowerment + ecological service" model, transforming service outsourcing from a mere "cost center" to a "value center" [1] - The service outsourcing industry is projected to achieve high-quality development under digital transformation, technological innovation, and policy support, becoming a significant engine for promoting service trade and digital trade [1] Group 3 - Relevant A-share concept stocks mentioned include Supercom and Kanglong Chemical [1]

Investment Rating - The industry rating is "Outperform the Market" [7] Core Insights - The report emphasizes the positive changes in the Biodefense Act and highlights the investment opportunities in external demand-oriented CXO companies due to the expected improvement in overseas financing and the easing of policy uncertainties [4][26] - The report notes that the recent Federal Reserve interest rate cut is expected to enhance overseas investment in the biotech sector, which will benefit CDMO companies through increased overseas orders [4][21] - The new Biodefense Act is less stringent than previous versions, which is expected to have a limited impact on external demand-oriented CXO companies, potentially lifting valuation pressures on the sector [4][26] Summary by Sections Market Review - During the week of December 8-12, 2025, the CITIC Pharmaceutical Index fell by 1.1%, underperforming the CSI 300 Index by 1.0 percentage points, ranking 15th among CITIC's primary industry classifications [3][32] - Year-to-date, the CITIC Pharmaceutical and Biotech Index has risen by 15.6%, underperforming the CSI 300 Index by 0.8 percentage points, ranking 16th among CITIC's industry classifications [3][32] - The top five performing stocks for the week were: Zhaoyan New Drug (+23.4%), Rejing Biotech (+16.8%), Haichuang Pharmaceutical (+13.9%), Wanze Co. (+13.4%), and Zhongyao Holdings (+13%) [3][49] Investment Opportunities - The report suggests focusing on innovative drugs, particularly those with revenue and commercialization capabilities, as well as potential big BD targets based on technological and industrial trends [5] - It also highlights opportunities in medical devices, especially in areas like endoscopy and robotics, and emphasizes the importance of innovative consumables supported by national policies [5] - The report indicates a shift towards domestic demand-driven companies as the central economic work conference emphasizes building a strong domestic market [5] Recommendations - The report recommends a focus on the following companies: Kangfang Biotech, WuXi AppTec, Kanglong Huacheng, Baiaosaitu, Bairen Medical, and Kangzhong Medical for December [5][12]

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

Group 1 - The core point of the news is that Kanglong Chemical conducted three block trades on December 12, totaling 1.484 million shares and a transaction amount of 44.0624 million yuan, with one trade executed at a discount rate of 0.90% [1][2] - Institutional proprietary seats participated in all three trades, with a total transaction amount of 44.0624 million yuan and a net purchase of 35.568 million yuan [1][2] - Over the past three months, Kanglong Chemical has recorded four block trades with a cumulative transaction amount of 67.6949 million yuan [1] Group 2 - The closing price of Kanglong Chemical on December 12 was 29.91 yuan, reflecting an increase of 2.96%, with a daily turnover rate of 2.45% and a total transaction amount of 1.035 billion yuan [1] - The net inflow of main funds for the day was 36.8064 million yuan, and the stock has increased by 2.40% over the past five days, with a total net inflow of 47.4292 million yuan [1] - The latest financing balance for the stock is 1.098 billion yuan, with an increase of 17.8699 million yuan over the past five days, representing a growth rate of 1.65% [2]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 （股份代號：3759） Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年12月11日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-066 康龙化成（北京）新药技术股份有限公司 ...

Investment Rating - The industry investment rating is "Overweight (Maintain)" [5] Core Viewpoints - The release of the first version of the commercial health insurance innovative drug directory marks a significant reform in China's pharmaceutical payment system, providing a clear commercial outlook for high-value innovative drugs [5][8] - The directory includes 19 drugs, focusing on key areas such as oncology, rare diseases, and Alzheimer's disease, which will enhance the accessibility and market penetration of these products [5][8] - The policy direction clearly supports "true innovation," with a low selection rate of approximately 15.7%, highlighting the recognition of differentiated innovative products with significant clinical advantages [8] Summary by Sections Recent Industry Performance - The industry has shown relative returns of -1.43% over the past month, -11.86% over the past three months, and -7.77% over the past year compared to the CSI 300 index [3] Key Events - The release of the dual directories on December 7, 2025, by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security is a pivotal moment for the pharmaceutical industry [5][8] Investment Highlights - The breakthrough in payment bottlenecks directly benefits high-value innovative drugs, such as CAR-T therapies, by significantly reducing patient out-of-pocket expenses through commercial insurance reimbursement [8] - The opening of the payment side not only benefits pharmaceutical companies but also stimulates product innovation demand in commercial health insurance and drives research and production service needs in cutting-edge fields like cell and gene therapy [8] - Recommended companies include those with significant products included in the new national medical insurance directory or the commercial health insurance innovative drug directory, as well as leading biotech firms in the CAR-T field [8]

Group 1 - The core point of the article highlights a significant block trade involving Kanglong Chemical on December 10, with a transaction volume of 810,000 shares and a transaction amount of 23.63 million yuan, executed at a price of 29.14 yuan, which represents a discount of 0.78% compared to the closing price of the day [1] Group 2 - On December 10, Kanglong Chemical's closing price was 29.37 yuan, reflecting an increase of 0.93%, with a daily turnover rate of 1.06% and a total transaction amount of 439 million yuan, alongside a net inflow of main funds amounting to 6.76 million yuan [1] - Over the past five days, the stock has seen a cumulative increase of 1.84%, while the total net outflow of funds during this period reached 79.28 million yuan [1] - The latest margin financing balance for Kanglong Chemical stands at 1.104 billion yuan, with an increase of 20.32 million yuan over the past five days, representing a growth rate of 1.88% [1] - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, with a registered capital of 1.778 billion yuan [1]

机构专用席位卖出额排名：华统股份(1765.68万元)、万达信息(665万元)。 成交价方面，共4只股票平价成交，1只股票溢价成交，66只股票折价成交；掌趣科技溢价成交，溢价率 为13.78%；蒙泰高新、固高科技、英思特折价率居前，折价率依次为22.05%、20.38%、19.9%。 Wind数据显示，今日（12月10日）A股共71只个股发生大宗交易，总成交15.21亿元，其中金发科技、 沪硅产业、航天工程成交额居前，成交额依次为1.91亿元、1.07亿元、8618.9万元。 机构专用席位买入额排名：沪硅产业(1.07亿元)、祥源文旅(5179.21万元)、航天工程(3921.84万元)、华 森制药(2842.93万元)、深桑达A(2788.5万元)、康龙化成(2363.25万元)、南矿集团(2295.88万元)、特发服 务(2208.45万元)、华仁药业(1936.79万元)、立达信(1876.66万元)、武汉凡谷(1867.58万元)、强达电路 (1811.8万元)、芯联集成-U(1682.2万元)、利源股份(1392.3万元)、圣诺生物(1361.15万元)、海光信息 (1059.75万元)、北京人力( ...